Exact Sciences to acquire Thrive Earlier Detection Corp. in cash and stock deal worth up to $2.15 billion

/ / News

Exact Sciences Corp. said Tuesday it has agreed to acquire Thrive Earlier Detection Corp. in a cash and stock deal worth up to $2.15 billion. Thrive Earlier is a health care company that aims to bring early cancer detection into routine medical care. The deal is expected to close in the first quarter of 2021. “Combining Thrive’s pioneering early-stage screening test, CancerSEEK, with Exact Sciences’ best-in-class scientific platform, clinical organization, and commercial infrastructure will establish Exact Sciences as a leading competitor in blood-based, multi-cancer screening,” the company said in a statement. The cancer screening market is worth more than $25 billion, said the statement. Exact Sciences shares rose 1.8% premarket and have gained 15% in the year to date, while the S&P 500 has gained 5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.